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Abstract 
Accurate assessment of SARS-CoV-2 immunity in the population is critical to 
evaluating vaccine efficacy and devising public health policies. Whilst the exact nature 
of effective immunity remains incompletely defined, SARS-CoV-2-specific T cell 
responses are a critical feature of the immune response that will likely form a key 
correlate of protection against COVID-19. Here, we developed and optimised a high-
throughput whole blood-based assay to determine the T cell response associated with 
prior SARS-CoV-2 infection and/or vaccination amongst 156 healthy donors and 67 
cancer patients. Following overnight in vitro stimulation with SARS-CoV-2-specific 
peptides, blood plasma samples were harvested and analysed for TH1-type effector 
cytokines (IFN-g and IL-2). Amongst healthy donors, highly significant differential IFN-
g+/IL-2+ SARS-CoV-2-specific T cell responses were seen amongst vaccinated or 
previously infected COVID-19-positive individuals in comparison to unknown/naïve 
individuals (P < 0.0001). IL-2 production from T cells in response to SARS-CoV-2 
derived antigens was a highly predictive diagnostic assay (P < 0.0001; 96.0% 
sensitivity, 93.9% specificity); measurement of IFN-g+ SARS-CoV-2 specific T cell 
responses was equally effective at identifying asymptomatic (antibody and T cell 
positive) participants. A single dose of COVID-19 vaccine induced IFN-g and/or IL-2 
SARS-CoV-2-specific T cell responses in 28/29 (96.6%) of healthy donors, reducing 
significantly to 27/56 (48.2%) when measured in cancer patients (P = 0.0003). Overall, 
this cost-effective standardisable test ensures accurate and comparable assessments 
of SARS-CoV-2-specific T cell responses amenable to widespread population 
immunity testing.  
  
 . CC-BY-NC-ND 4.0 International licenseIt is made available under a 
 is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)
The copyright holder for this preprint this version posted June 3, 2021. ; https://doi.org/10.1101/2021.06.02.21258218doi: medRxiv preprint 
 3 
Background 
As the COVID-19 pandemic continues, there is an increasing focus on understanding 
how adaptive immune responses generated from severe acute respiratory syndrome 
coronavirus 2 (SARS-CoV-2) infection and/or vaccination provide protection from 
future infection. Although the exact determinants of effective immunity from re-
infection with SARS-CoV-2 remain to be deciphered, multiple recent studies have 
revealed that virus-specific T cell responses develop in nearly all individuals with 
confirmed SARS-CoV-2 infection (1-4), with responses persisting for at least six 
months post-infection (5). Traditional means of assessing viral antigen-specific T cell 
responses utilise flow cytometry or ELISpot-based readouts; however, neither 
approach is standardisable across multiple laboratories, cost-effective, or amenable 
to high-throughput processing, thus precluding their use for larger scale population 
immunity screen. In addition, current commercially available immunoassays that 
detect cellular immune responses to SARS-CoV-2 solely measure IFN-g released by 
antigen-specific T cells (6), even though other TH1-type cytokines may be better 
indicators of anti-viral response (5). To overcome these limitations, existing whole 
blood-based in vitro immunodiagnostics, such as those used for measuring 
Mycobacterium tuberculosis-specific T cell responses (7), can be adapted to measure 
virus-specific T cell responses in a high-throughput, standardisable manner. 
Specifically, this T cell immunoassay measures cytokines in the plasma released by 
antigen-specific T cells following stimulation with specific peptides spanning antigenic 
regions of the pathogen. This approach is gaining recognition as a potentially powerful 
diagnostic tool for managing the COVID-19 pandemic (8-10).  
Monitoring immunological responses to SARS-CoV-2 is of particular 
importance amongst the elderly and immunosuppressed, given the significantly higher 
mortality rates observed in these groups (11). Recent studies have associated higher 
rates of COVID-19 morbidity and mortality with sub-optimal adaptive immune 
responses (12). The incidence of cancer is also increased in the elderly where a 
declining adaptive immune system, as well as age-associated inflammation, are 
factors in disease progression. Given that influenza vaccines induce weaker immune 
responses in the elderly and in cancer patients (13, 14), measuring adaptive immune 
responses to SARS-CoV-2 in vaccinated individuals belonging to these groups is 
important. Indeed, early indications suggest that cancer patients, in particular those 
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on active treatments such as chemotherapy, were significantly less likely to mount 
antibody and T cell responses to the Pfizer-BioNTech SARS-CoV-2 mRNA vaccine, 
(15). 
Here, we adapted and optimised a widely utilised in vitro whole blood 
stimulation assay to determine the presence of SARS-CoV-2-specific TH1-type (IFN-g 
/ IL-2) cellular immune responses in healthy donors, to assess T cell responses 
generated from prior infection, whether the participant was symptomatic or not, and 
as a readout of vaccine efficacy amongst healthy donors and cancer patients. We 
demonstrate high sensitivity and specificity of this assay to identify or exclude prior 
SARS-CoV-2 infection and/or successful COVID-19 vaccination. Going forward, it is 
imperative to utilise such tests to understand the precise contribution of T cell 
responses with regards to long-term immunity to SARS-CoV-2 infection, in particular 
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Participants were recruited to this research project between February-April 2021. A 
healthy donor cohort (n = 156) comprised university staff and students attending 
Cardiff University’s COVID-19 Screening Service or members of the public attending 
a Cardiff-based GP practice. All participants were otherwise healthy and did not report 
taking any current immunosuppressive treatment. In addition, patients with a range of 
solid-organ cancers (n = 67) were recruited from Velindre Cancer Centre prior to 
receiving their first COVID-19 vaccine (see Table 1 for basic characteristics). All 
participants were stratified based on self-reported and/or laboratory evidence of a prior 
SARS-CoV-2 infection. Participants reporting no prior positive test were defined as 
‘unknown/naïve’. To measure immunological responses generated to COVID-19 
vaccination, baseline blood samples were taken immediately preceding the first dose; 
an additional post-vaccination blood sample was taken 3-6 weeks later. Only 
participants donating a blood sample both pre- and post-vaccination were included in 
the analyses. All vaccinated participants received either Pfizer (BNT162b2) mRNA 
vaccine or AstraZeneca (ChAdOx1 nCoV-19) vaccine.  
This study received ethical approval from the Wales Cancer Bank (WCB No. 
21/004), the Newcastle & North Tyneside 2 Research Ethics Committee (IRAS ID: 
294246) and Cardiff University School of Medicine Research Ethics Committee 




All SARS-CoV-2 peptides were dissolved according to manufacturer’s instructions 
(Miltenyi Biotec). A single SARS-CoV-2-specific S-/NP-/M-combined peptide pool was 
created, comprising mainly 15-mer sequences with 11-amino acid overlap, covering 
the entire spike (S1 and S2) protein (S), nucleocapsid phosphoprotein (NP) and 
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A single 6ml or 10ml sodium heparin vacutainer (BD) tube of venous blood was 
collected from each participant and processed in the laboratory within 12 hours of 
blood draw. Whole blood samples were aliquoted into microcentrifuge tubes (Thermo 
Scientific) containing pre-aliquoted peptides, alongside additional tubes containing 
phytohaemagglutinin (Sigma) (positive control) or nothing (negative control). Samples 
were incubated at 37°C for 20-24 hours. Tubes were then centrifuged at 3000g for 2 
minutes before harvesting plasma from the top of each blood sample. Plasma samples 
were stored at -20°C for up to one month prior to running cytokine detection assays. 
 
Detection of anti-SARS-CoV-2 RBD IgG Antibodies 
An in-house direct ELISA was developed as previously described (16-19), with some 
modifications. Maxisorp (Nunc, Loughborough, UK) 96-well plates were coated with 
RBD protein (recombinantly generated in a mammalian expression system, in house) 
at 2 µg/ml in bicarbonate buffer, pH 9.6 at 4°C overnight; wells were blocked for 1 hour 
at room temperature with 3% w/v non-fat dried milk powder (Sigma Aldrich, # 70166-
500G) in phosphate-buffered saline containing 0.1% Tween 20 (PBS-T), washed in 
PBS-T. Dilutions of patient sera (1 in 50 in 1% Milk PBS-T), were added in duplicate 
to wells coated with RBD protein and incubated for 2 hours at room temperature. Wells 
were washed three times with PBS-T then incubated (1 hour, room temperature) with 
secondary antibody (donkey anti-human IgG F(ab')₂-horseradish peroxidase (HRP); 
#709-036-149, Jackson ImmunoResearch, Ely, UK) for 1 hour at room temperature. 
After washing (x3), plates were developed using O-phenylenediamine dihydrochloride 
(OPD, SIGMAFASTTM; Sigma-Aldrich, # P9187-50SET) and the optical density (OD) 
measured at 492 nm. Assay validation, including intra-/inter-assay CVs for this assay 
have been previously described (17, 19).  
 
Cytokine Detection  
IFN-g was measured using the IFN-g ELISA MAX Deluxe kit (BioLegend) and 
performed according to manufacturer’s instructions. Microplates were read at 450nm 
immediately following the addition of stop solution (2N H2SO4). IFN-g was quantified 
by extrapolating from the standard curve using Graphpad Prism. Values below the 
lower limit of detection of the assay were recorded as 7.81 pg/ml. IL-2 was measured 
using a custom Bio-Plex Pro Human Cytokine Set (Bio-Rad) and performed according 
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to manufacturer’s instructions. The mean fluorescent intensity of the cytokine beads 
was measured on a Bio-Plex 200 (Bio-Rad). Cytokine concentration was calculated 
from control curves of standards provided in the kit. Values below the lower limit of 
detection of the assay were recorded as 6.28 pg/ml. 
 
Statistics 
GraphPad Prism Version 9 was used for all statistical analyses of datasets. Dataset 
normality was tested using the Shapiro-Wilk test. Significance was determined using 
either Kruskal-Wallis tests with corrections for multiple comparisons made using the 
Dunn test, or Mann-Whitney tests, as indicated in the figure legends. Correlation 
analyses were performed using linear regression. All tests were performed two-sided 
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Results 
Prior analysis of the SARS-CoV-2-specific T cell cytokine profile, measured in 
supernatants of ex vivo peptide-stimulated ELISpot cultures or whole blood assays,   
revealed that TH1-type IFN-g+ and IL-2+ responses dominate effective, functional 
SARS-CoV-2-specific T cell responses (5, 10). The magnitude of TH1-type responses 
generated to the SARS-CoV-2 S-/NP-/M-combined peptide pool was assessed 
amongst healthy donor participants who had either received a prior vaccination (n = 
52), a confirmed prior infection (n = 15) (PCR positive swab from nasopharynx or saliva 
sample and/or a strong history of infection with positive measured antibody responses 
to SARS-CoV-2) or no known history of infection (n = 88). Highly significant differential 
IFN-g-positive and IL-2-positive SARS-CoV-2-specific T cell responses were seen 
amongst vaccinated or previously infected (non-vaccinated) COVID-19-positive 
individuals in comparison to unknown/naïve individuals (Figure 1A; P < 0.0001 and 
Figure 1B; P < 0.0001, respectively). There was no significant difference in the 
magnitude of IFN-g or IL-2 production between vaccinated and infected participants 
(Figure 1A and 1B, respectively). Amongst all vaccinated, infected or unknown/naïve 
participants, there were highly significant correlations between IFN-g and IL-2 
production, despite a propensity for increased (>20 pg/ml) IFN-g+ SARS-CoV-2-
specific T cell responses without a measurable IL-2 response amongst unknown/naïve 
donors (Figure 1C).  
Next, we correlated participant T cell responses with anti-SARS-CoV-2 RBD 
IgG antibodies. There was a strong concordance, albeit not significant correlation, 
between the presence of both cellular and humoral immune responses in all 
vaccinated and previously infected participants: only 1/15 (6.7%) previously infected 
participant had a positive antibody response (>0.27) without a measurable IFN-g+ or 
IL-2+ T cell response. All 52 vaccinated participants demonstrated a measurable IFN-
g+ or IL-2+ T cell response, although two were antibody negative (<0.27) (Figures 1D 
and 1E). To investigate whether the increased T cell responses observed amongst 
naïve/unknown participants with no history of confirmed infection was indicative of 
asymptomatic SARS-CoV-2 infection, we further compared the magnitude of IFN-g+ or 
IL-2+ T cell responses with evidence of antibody seroconversion; a significant 
correlation between T cell response and the magnitude of anti-SARS-CoV-2 RBD IgG 
antibodies was noted for unknown/naïve participants (IFN-g: P = 0.0002, Figure 1D; 
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IL-2: P = 0.0010, Figure 1E). Ten such participants were identified as having both a 
positive antibody response (>0.27) and raised (above median) IFN-g+ T cell response, 
as indicated (Figure 1D), and eight participants also had a positive antibody and 
increased IL-2+ T cell response (Figure 1E), consistent with the adaptive immune 
responses generated in the majority of vaccinated or previously infected participants. 
Given these participants self-reported no prior confirmed COVID-19 test or symptoms 
associated with COVID-19 during the pandemic, the presence of both a SARS-CoV-
2-specific T cell and antibody response is highly indicative of prior asymptomatic 
infection.  
 When assessing the utility of measuring SARS-CoV-2-specific T cell responses 
to identify those who have received prior COVID-19 vaccination and/or been 
previously infected, Youden’s index revealed an optimal cut-off value of >23.55 pg/ml 
IFN-g, achieving a sensitivity of 93.59% (95% CI 85.9-97.2%) and specificity of 80.8% 
(95% CI 70.7-88.0%) (AUC = 0.94 (95% CI 0.91-0.98); P < 0.0001; Figure 1F). 
Measuring IL-2+ T cell response as the readout adjusted the sensitivity and specificity 
to 96.0% (95% CI 88.8-98.9%) and 93.9% (95% CI 86.5-97.4%), respectively, at an 
optimal cut-off value of >20.17 pg/ml IL-2 (AUC = 0.96 (95% CI 0.93-1.00); P < 0.0001; 
Figure 1G). 
Next, we further evaluated eleven non-vaccinated COVID-19-positive 
convalescent participants reporting mild to moderate severity of associated symptoms, 
and ten non-vaccinated participants reporting no prior associated symptoms and for 
whom both IFN-g and IL-2 data was available (Figure 2A), to determine the 
functionality of SARS-CoV-2-specific T cells induced by prior asymptomatic infection. 
The magnitude of IFN-g production was reduced in asymptomatic participants (P = 
0.061, Figure 2A and 2B); furthermore, a significant reduction in IL-2 production was 
noted (P = 0.0011, Figure 2A and 2C). When assessing all TH1 responses by 
participant infection and symptom status and using optimal cut-offs defined above to 
identify positive responses, dual-producing IFN-g+/IL-2+ SARS-CoV-2-specific T cell 
responses were present in 10/11 (90.9%) of symptomatic participants, reducing to 
7/10 (70.0%) amongst asymptomatic participants (Figure 2D). Given the diminished 
nature of the SARS-CoV-2-specific TH1-type cytokine production in asymptomatic 
donors, both IFN-g and IL-2 are equally useful readouts when assessing for the 
presence of T cell responsiveness.  
 . CC-BY-NC-ND 4.0 International licenseIt is made available under a 
 is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)
The copyright holder for this preprint this version posted June 3, 2021. ; https://doi.org/10.1101/2021.06.02.21258218doi: medRxiv preprint 
 10 
SARS-CoV-2-specific T cell responses amongst unknown / naïve participants, 
i.e. those with no measurable anti-SARS-CoV-2 RBD IgG antibodies and no prior 
confirmed history of infection, were rare, with 3/76 (3.8%) displaying a dual IFN-g+/IL-
2+ response and 12/76 (15.8%) displaying an IFN-g+/IL-2- response. This could be 
indicative of pre-existing, cross-reactive T cells, or a terminally differentiated effector 
T cell response. However, further studies are required to ascertain whether those 
participants with raised anti-SARS-CoV-2-specific TH1 responses without 
seroconversion have been infected by SARS-CoV-2. Interestingly, this discordant 
immune response has also been reported when monitoring intra-familial exposure to 
the virus (20). 
Finally, we tracked T cell and antibody responses pre- and post-single dose 
SARS-CoV-2 vaccination amongst a cohort of healthy controls and a cohort of cancer 
patients with solid tumours. Robust priming of SARS-CoV-2-specific T cells was 
observed amongst healthy controls, with 28/29 (96.6%) mounting an IFN-g+ response 
>23.55 pg/ml (Figure 3A) and 20/22 (90.9%) mounting IL-2+ responses >20.17 pg/ml 
(Figure 3B). In contrast, only 27/56 (48.2%) and 18/31 (58.1%) of cancer patients 
mounted an IFN-g (Figure 3A) or IL-2 (Figure 3B) response following single dose 
SARS-CoV-2 vaccination, respectively. Furthermore, anti-SARS-CoV-2 RBD IgG 
antibody responses were also compromised in cancer patients though to a lesser 
degree than the T cell response, with 42/54 (77.8%) of cancer patients vs. 27/28 
(96.4%) of healthy controls reaching the threshold of positivity in our antibody test 
(Figure 3C). This may reflect a limitation of the whole blood-based SARS-CoV-2 T cell 
assay in that insufficient numbers of lymphocytes may be present to detect such a 
response; this may be a particular problem in cancer given that lymphopenia is a 
common occurrence. However, such a situation is also likely to hamper the induction 
of long-term T cell memory formation. 
Overall, these data highlight the power of measuring SARS-CoV-2-specific T 
cell responses as a means for identifying prior COVID-19 infection, vaccination 
efficacy and/or potential future immunity from re-infection status. 
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Discussion 
This study demonstrates the utility of a high-throughput, standardisable T cell 
immunoassay to accurately detect SARS-CoV-2-specific T cell responses. In order to 
control future outbreaks and identify at-risk individuals, the exact constituents of 
effective COVID-19 immunity at a population level must be understood. When used 
alongside measurements of virus-specific antibodies, T cell response readouts 
represent a powerful, additional measure of potential immunity from COVID-19, with 
a higher degree of confidence than either measurement on their own, in particular 
given the concern on the longevity of measurable antibody responses (21-23). In 
addition, the FDA’s decision to issue emergency use authorisation for a SARS-CoV-2 
T cell test highlights the growing acceptance and usefulness of T cell testing for the 
clinical management of certain patient groups (24). 
Here, we show that measuring plasma TH1-type effector cytokines from SARS-
CoV-2 peptide-stimulated whole blood can accurately detect the presence of a cellular 
immune response to SARS-CoV-2, distinguishing those who have received prior 
vaccination and/or infection from uninfected healthy donors with a high degree of 
sensitivity and, in particular for IL-2, specificity. These results are consistent with 
comprehensive analyses of the cytokine profile released by SARS-CoV-2-specific T 
cells measured in whole blood-based assays or ELISpot / cell culture supernatants, 
which showed that IL-2 and IFN-g are the dominant cytokines (5, 10, 25). However, 
the relevance of an IFN-g-positive, IL-2-negative SARS-CoV-2-specific T cell response 
in uninfected donors with respect to long-term immunity requires further investigation.  
The peptides used in our immunoassay predominantly stimulate CD4+ T cell 
responses, and cover all major immunodominant regions of the virus, including those 
in the spike, membrane and nucleocapsid proteins, as recently defined (26).  TH1-type 
responses to these immunogenic regions were detected in the vast majority of 
convalescent SARS-CoV-2 infected and/or vaccinated individuals, in keeping with 
prior findings (26, 27), although convalescent asymptomatic donors and a minority of 
naïve individuals demonstrate low-level reactivity. Prior studies have revealed the 
functionality and magnitude of adaptive immune responses to SARS-CoV-2 were 
significantly lower in mild cases of COVID-19 in comparison to severe (5), potentially 
the result of lower viral loads (27, 28). In accordance with this, our study revealed that 
production of IFN-g and IL-2 was lower in COVID-19-convalescent asymptomatic 
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participants. However, a recent longitudinal analysis of asymptomatic SARS-CoV-2 
infection identified an increased, highly functional IFN-g and IL-2 response within 3 
months of infection that declined faster than in symptomatic individuals (10). 
Differences in post-infection sampling times likely account for the discrepancy in 
associations between SARS-CoV-2-specific T cell responses and COVID-19 symptom 
severity, given that the majority of our participants were infected ~6 months prior to 
blood sampling. However, it is encouraging to note that T cell responses were still 
present and functional over this timeframe in nearly all SARS-CoV-2-infected 
convalescent and/or vaccinated participants, even in those up to 12 months post-
infection, corresponding well with prior studies describing the longevity of anti-SARS-
CoV-2 T cell immunity (5). Whether these responses provide immune protection, 
especially to new emerging mutant variants of the SARS-CoV-2 virus, warrants further 
investigation in larger prospective cohorts. In addition, further downstream analyses 
incorporating other coronaviruses and additional antigenic regions are necessary to 
ascertain whether cross-reactive T cell responses play a role in SARS-CoV-2 
immunity. 
Future studies are on-going to evaluate the durability of these measured T cell 
responses in our participants, comparing healthy subjects with immunocompromised 
patients, such as those with cancer. After the first dose of vaccine in cancer patients, 
a significantly weaker induction of cellular and, to a lesser extent, humoral responses 
was found, corroborating similar observations in other studies (15). These data 
provide further support to recent calls for cancer patients to be prioritised for booster 
vaccines and longer-term immunological monitoring.  
In summary, we describe an immunoassay that accurately and rapidly identifies 
the presence of SARS-CoV-2-specific T cell responses, both helping to elucidate the 
adaptive immune status of previously infected and/or vaccinated individuals, and 
diagnosing previously unsuspected past infection. Incorporating qualitative T cell 
response data in population immunity studies, or individualised certifications of 
immunity, could have far reaching implications for government policy on lockdown 
restrictions, and more effectively assess vaccine efficacy in communities, highlighting 
the potential requirement for repeat vaccinations where immunity wanes.  
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Figure 1. SARS-CoV-2-specific T cell response identifies prior asymptomatic 
infection. IFN-g (A) and IL-2 (B) release in response to the SARS-CoV-2 S-/NP-/M-
combined peptide pool was measured in 156 evaluable participants, subdivided into 
those with prior COVID-19 vaccination (grey, n = 52), prior COVID-19-positive PCR 
test result (blue, n = 12-15), or those with no prior positive COVID-19 test, termed 
‘unknown/naïve’ (orange, n = 88). Statistical analyses indicate the results of a 
Kruskal-Wallis test with Dunn’s correction for multiple comparisons (**** P < 0.0001). 
(C) The SARS-CoV-2-specific IL-2+ T cell response was correlated with the IFN-g+ 
response, subdivided by participant status. The anti-SARS-CoV-2 RBD IgG antibody 
titre was correlated with the magnitude of IFN-g+ T cell response (D) and IL-2+ T cell 
response (E), with identified asymptomatic participants highlighted. Results of 
regression analyses are indicated. Sensitivity and specificity readouts for IFN-g (F) 
and IL-2 (G) were defined by receiver operating characteristic curves. Area under the 
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Figure 2. Asymptomatic participants exhibit reduced SARS-CoV-2-specific T 
cell functionality. (A) IFN-g and IL-2 T cell responses amongst eleven symptomatic 
and 10 asymptomatic SARS-CoV-2-infected donors is shown for each individual.  
IFN-g (B) and IL-2 (C) release by T cells in response to the SARS-CoV-2 S-/NP-/M-
combined peptide pool was measured in the symptomatic, asymptomatic and naïve 
donors (n = 76). P values resulting from Mann Whitney tests are shown (** P < 0.01). 
The proportion of symptomatic, asymptomatic and naïve participants mounting dual 
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Figure 3. Utilising SARS-CoV-2-specific T cell response measurements as a 
readout for COVID-19 vaccine efficacy amongst healthy donor and cancer 
patient cohorts. IFN-g+ (A) and IL-2+ (B) SARS-CoV-2-specific T cell responses and 
anti-SARS-CoV-2 RBD IgG levels (C) were measured before and 3-6 weeks after a 
single COVID-19 vaccination in healthy donors and cancer patients. Two-tailed P 
values resulting from Mann Whitney tests are shown. (D) Vaccination response rates 
(NR = no response, R = response) in terms of positive T cell (IFN-g, IL-2) or antibody 
(RBD IgG) response amongst each cohort is shown. P values indicate results from 
Fisher’s exact test. 
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  Male 25/68 (36.8%) 48/156 (30.8%) 
  Female 43/68 (63.3%) 108/156 (69.2%) 
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